Prof. He Huang
✓ Available through China Expert Care
Director, Institute of Hematology, Zhejiang University; Head of the Bone Marrow Transplantation Center; Chief Physician
Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine
Focus: CAR-T cell therapy and stem cell transplantation for leukaemia, lymphoma and multiple myeloma
Prof. Huang directs the Institute of Hematology at Zhejiang University and leads the Bone Marrow Transplantation Center at the First Affiliated Hospital of Zhejiang University School of Medicine. Senior author of a Nature study of non-viral, site-specific CAR-T cells for B-cell lymphoma, the first-in-human POLARIS trial of GPRC5D CAR-T cells for multiple myeloma, and a study of allogeneic CD7 CAR-T cells for CD7-positive leukaemia.
Conditions: CAR-T cell therapy
Selected publications
- Nature, 2022 (senior author): Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. PubMed 36045296
- Lancet Haematology, 2023 (senior author): GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. PubMed 36725117
- Cell Research, 2022 (senior author): Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. PubMed 36151216
Profile on the hospital website: https://www.zy91.com/department/doctor/74/452
Request a written opinion from Prof. He Huang
Send your records. A medical coordinator will reply within 24 hours.
Start here